(Alliance News) - Bivictrix Therapeutics PLC announced on Monday it has received "positive" in vivo test results from its BVX002 solid tumour programme. Read More
(Alliance News) - Stock prices in London closed higher on Monday, as sentiment remains positive ahead of some key economic data. Read More
(Alliance News) - Bivictrix Therapeutics PLC on Monday announced its intention to delist from AIM in favour of pursuing funding as a private entity to advance its pipeline. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday. Read More
(Alliance News) - Stocks in London are called to open higher, as some calm spreads over markets a week after the global sell-off which shook investors. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Bivictrix Therapeutics PLC on Wednesday said its BVX001 drug has been granted special status by the US Food and Drug Administration. Read More
Bivictrix Therapeutics PLC - Macclesfield, England-based biotechnology company focused on cancer therapies - Says final sequences have been selected for its second programme BVX002, an antibody drug conjugate or ADC targeting solid tumour indications. Emerging data identifies high-grade serous ovarian cancer as one of the lead indications. Company says it is on track to identify the development lead in 2024. Says findings represent "significant unmet need and commercial potential for BVX002". Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Bivictrix Therapeutics PLC on Thursday said its Bi-Cygni antibody-drug conjugate, BVX001, showed survival rates more than doubled in a pre-clinical model of acute myeloid leukaemia. Read More
(Alliance News) - Bivictrix Therapeutics PLC on Tuesday said it has appointed Adrian Howd as chief financial officer and chief business officer as CFO Alex Hughes is set to step down next Friday after just seven months in the role. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday. Read More
(Alliance News) - Bivictrix Therapeutics PLC on Wednesday said it has been granted a US patent for lead asset BVX001. Read More
(Alliance News) - Bivictrix Therapeutics PLC on Wednesday said it has raised GBP2.1 million through a placing and subscription of 16.4 million shares. Read More
Bivictrix Therapeutics PLC on Wednesday - Macclesfield, England-based biotechnology company focusing on cancer therapies - Announces a proposed fundraise of over GBP2 million by way of a conditional placing to investors. The placing will raise GBP1.2 million before expenses through the issue of 9.2 million shares at 13 pence per share. Adds the subscription of shares will raise around GBP800,000 before expenses through the issue of 6.8 million new shares. Says issue of shares is subject to shareholder approval at the general meeting set to take place on August 8. Read More
(Alliance News) - BiVictriX Therapeutrics PLC announced on Monday that it had received positive final data from a second in vivo efficacy study of BVX001, an antibody drug for treatment of acute myeloid leukaemia. Read More
Bivictrix Therapeutics PLC - Macclesfield, England-based biotechnology company focusing on cancer therapies - Posts positive interim data in its second preclinical efficacy study of its lead programme BVX001 that treats acute myeloid leukaemia. Bivictrix says that the efficacy study is due to be completed before the end of June, and is an attempt to assess the anti-tumour responses of BVX001 at a dose of 10 kilograms twice-weekly. The study shows that BVX001 demonstrates an 89% tumour regression at day 18 following administration of six out of the total eight planned doses. Read More